DiaGenic ASA Patent Allowed in Canada

Published: Apr 11, 2013

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) has received notice of allowance for its Canadian family 2 patent application. The allowed claims cover the use of a set of gene sequences in blood essential for the diagnosis of, among other diseases, Alzheimer’s disease and stages thereof. The patent when granted will be valid until 2023.

Back to news